Pharsight

Drugs that contain Dabrafenib Mesylate

1. Tafinlar patents expiration

TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415345 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US7994185 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(11 months from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(1 year, 5 months from now)

US9233956 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
May, 2029

(4 years from now)

US9233956

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Nov, 2029

(5 years from now)

US7994185

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US8415345

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(6 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(6 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(9 years from now)

US11504333 NOVARTIS Pharmaceutical composition
Jun, 2038

(14 years from now)

US11504333

(Pediatric)

NOVARTIS Pharmaceutical composition
Dec, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
Orphan Drug Exclusivity(ODE-147) Jun 22, 2024
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030
New Indication(I-908) Mar 16, 2026
New Indication(I-894) Jun 22, 2025
Pediatric Exclusivity(PED) Dec 22, 2025
New Indication(I-745) Jun 22, 2020
New Indication(I-678) Jan 08, 2017
M(M-170) Nov 20, 2018
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-47) May 29, 2020
Orphan Drug Exclusivity(ODE-58) Jan 09, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
Orphan Drug Exclusivity(ODE) May 29, 2020
New Chemical Entity Exclusivity(NCE) May 29, 2018

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...

Dosage: CAPSULE;ORAL; TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

TAFINLAR family patents

Family Patents